KEEPING YOU UP TO DATEClearstate Healthcare InsightsClearstate Insights is your single source to all our latest healthcare intelligence. From recently published reports offering thought-provoking analysis, to information about new products and services, we will ensure you are always kept informed. Sign up to Clearstate’s newsletter
How Indonesia’s healthcare transformation will impact its IVD market Indonesia’s in-vitro diagnostics (IVD) market will recover… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Asia | Centralised Diagnostics (CEDx) | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT)
How inflation will impact Brazil’s IVD market Brazil’s in-vitro diagnostics (IVD) market will recover in… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Uncategorised | Americas
Testing times: opportunities for IVD companies in 2023 Growth opportunities from covid-19 have helped fuel rapid… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Point-of-care testing (POCT) | Tissue Diagnostics (TDx) | Americas | Asia | Europe | Global | Middle East & Africa
Going global: opportunities for Chinese IVD companies Opportunistic growth opportunities from covid-19 have helped… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Middle East & Africa
How Vision 2030 is driving growth in Saudi Arabia’s IVD market The incidence of cardiovascular diseases (CVD) in… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Middle East & Africa | Centralised Diagnostics (CEDx) | IVD Gateway | Molecular Diagnostics (MDx)
Middle East IVD market to recover to pre-pandemic growth rates from 2024 The Middle East IVD market has mostly recovered to… Centralised Diagnostics (CEDx) | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Middle East & Africa | Centralised Diagnostics (CEDx) | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT)
Cardiac biomarker testing market outlook in Latin America The incidence of cardiovascular diseases (CVD) in… In-vitro diagnostics | Point-of-care testing (POCT) | Americas | IVD Gateway | Point-of-care testing (POCT)
The future of point-of-care cardiac biomarker testing With longer life expectancies in APAC, there is an… In-vitro diagnostics | Point-of-care testing (POCT) | Global | IVD Gateway | Point-of-care testing (POCT) | The Gateway
Cardiac biomarker testing market outlook in Asia-Pacific The incidence of cardiovascular diseases (CVD) in… In-vitro diagnostics | Point-of-care testing (POCT) | Asia | IVD Gateway | Point-of-care testing (POCT)
Proportion of cancer biomarker testing done with NGS expected to double in 2022 compared to 2019 Proportion of cancer biomarker testing done with NGS… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
2022 healthcare megatrends shaping IVD 2022 healthcare megatrends shaping IVD… In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Point-of-care testing (POCT) | Asia | Europe | Middle East & Africa | IVD Gateway | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Point-of-care testing (POCT)
Point-of-care vs. lab-based covid-19 testing Covid-19 testing has emerged as a top priority for clinical… In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Asia | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT)
Sign up to our free newsletterThe latest trends and insights into the IVD and Surgical sectors, from our specialists and analysts, delivered directly to your inbox. Sign up to Clearstate’s newsletter today. Sign up now